Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 27, 2026Immunotherapy

Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhiqiang LiYLY LiYZYuhan Zhang

Discussion

Loading...

Member takes

Overview

Case report demonstrates rapid resolution of severe cutaneous toxicity in gastric cancer, indicating a potential salvage regimen for refractory immunotherapy adverse events.

Key Points

  • To describe the therapeutic management of a severe, refractory cutaneous immune-related adverse event induced by PD-1/CTLA-4 bispecific antibody therapy using low-dose interleukin-2 and thalidomide.
  • Clinical case evaluation of a patient with gastric cancer who developed severe erythema and pruritus after treatment with the PD-1/CTLA-4 bispecific antibody combination iparomlimab and tuvonralimab.
  • Administration of low-dose interleukin-2 combined with thalidomide alongside ongoing corticosteroid therapy after failure of standard corticosteroids, intravenous immunoglobulin, and antihistamines.
  • Clinical improvement of severe erythema and pruritus was observed within 48 hours of starting low-dose interleukin-2 and thalidomide.
  • Complete resolution of all cutaneous immune-related adverse event lesions occurred at 2 weeks of combined therapy.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe9da10c91c1e92621ca0https://doi.org/10.1080/1750743x.2026.2722556
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dupilumab Can Be Effective for Immune-Related Adverse Event Dermatitis: A Case Report and Review of the Literature2026 · 1 citations
  2. 2Low-dose IL-2 therapy for immune-related adverse events via Tfh/Treg balance modulation: a prospective cohort and murine model study2026
  3. 3Advanced non-small cell lung cancer patient with a complete response and allergic immune-related adverse events by combined immunotherapy, including anti-CTLA-4 and anti-PD-1 antibodies: A case report2024
  4. 4Medical dilemma: Programmed death 1 blockade (sintilimab) therapy in patients suffering from tumours combined with psoriasis2024
  5. 5Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy2024 · 26 citations